{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:53:54Z","timestamp":1788836034457,"version":"build-2803163510"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The potential impact of NET (neuroendocrine tumor)-related disease burden on musculoskeletal health remains inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess the musculoskeletal status, its prognostic relevance and association with tumor aggressiveness in NET patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 41 patients with grade (G) 1, 2, or 3 gastroenteropancreatic (GEP) and lung NETs. Among them, 38 were selected for comparison with 47 healthy controls matched for age, sex and body mass index (BMI). The musculoskeletal health was assessed by dual-energy X-ray absorptiometry (DXA) scan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Within the NET group (median age=72 years old, 46% women), degraded TBS (trabecular bone score) was found in 71% of patients, with osteopenia affecting up to 59% at the femoral neck. The prevalence of hypovitaminosis D was 68%, whereas of low RSMI (relative skeletal muscle index) suggestive of sarcopenia 37%. Patients with advanced-stage NETs showed significantly lower L1-L4 BMD (bone mineral density), L1-L4 T-score, L1-L4 Z-score, 25-hydroxyvitamin D [25(OH)D] levels and BMI than those with earlier-stage disease. G2 NETs were associated with worse L1-L4 BMD, L1-L4 T-score, total hip T-score and diaphysis BMD than G1 NETs. In multivariate analysis, higher 25(OH)D levels and BMI were independently associated with longer progression-free survival (PFS), whereas higher Ki-67 was associated with shorter PFS. Correlation analyses showed inverse associations between Ki-67 and total hip T-score (rho = -0.314, p=0.048) and diaphysis BMD (rho = -0.354, p=0.025); age at NET diagnosis correlated with poorer bone parameters, whereas higher BMI was associated with better bone indices and RSMI. Compared with healthy controls, NET patients had significantly lower TBS, regardless of BMD, T-score or Z-score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NET patients showed a substantial burden of musculoskeletal impairment, with trabecular microarchitecture deterioration detectable despite BMD versus healthy controls. Advanced disease stage, higher grade and systemic treatment were associated with poorer bone health. Increased vitamin D levels and BMI were independently associated with longer PFS, supporting a potential relationship between nutritional-metabolic status and oncological outcomes. Low muscle mass was also frequent, although not significantly associated with tumor aggressiveness. These exploratory findings highlight the need for structured musculoskeletal assessment in NET patients and require validation in larger prospective studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1882735","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:38:26Z","timestamp":1782891506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone health in neuroendocrine tumors and prognostic implications beyond skeletal metastases"],"prefix":"10.3389","volume":"17","author":[{"given":"Andrea","family":"Casabella","sequence":"first","affiliation":[{"name":"Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Universita degli Studi di Genova Dipartimento di Medicina Interna e Specialita Mediche","place":["Genoa, Italy"]},{"name":"Rheumatology Unit, IRCCS AOM Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iderina","family":"Hasballa","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Universit\u00e0 degli Studi di Genova, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Arecco","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Universit\u00e0 degli Studi di Genova, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Boschetti","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Universit\u00e0 degli Studi di Genova, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche","place":["Genoa, Italy"]},{"name":"Endocrinology Unit, IRCCS AOM Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Della Sala","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Universit\u00e0 degli Studi di Genova, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Demontis","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Universit\u00e0 degli Studi di Genova, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Sulli","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Universita degli Studi di Genova Dipartimento di Medicina Interna e Specialita Mediche","place":["Genoa, Italy"]},{"name":"Rheumatology Unit, IRCCS AOM Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Vera","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, IRCCS AOM Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Veresani","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Universit\u00e0 degli Studi di Genova, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Universit\u00e0 degli Studi di Genova, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche","place":["Genoa, Italy"]},{"name":"Endocrinology Unit, IRCCS AOM Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Paolino","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Universita degli Studi di Genova Dipartimento di Medicina Interna e Specialita Mediche","place":["Genoa, Italy"]},{"name":"Rheumatology Unit, IRCCS AOM Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Albertelli","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Universit\u00e0 degli Studi di Genova, Dipartimento di Medicina Interna e Specialit\u00e0 Mediche","place":["Genoa, Italy"]},{"name":"Endocrinology Unit, IRCCS AOM Ospedale Policlinico San Martino","place":["Genoa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of neuroendocrine neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw Open"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01905-4","article-title":"Neuroendocrine neoplasms in the context of inherited tumor syndromes: a reappraisal focused on targeted therapies","volume":"46","author":"Ruggeri","year":"2023","journal-title":"J Endocrinol Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.003","article-title":"Lung and thymic carcinoids: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Baudin","year":"2021","journal-title":"Ann Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29099","article-title":"Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes","volume":"121","author":"Hallet","year":"2015","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000513249","article-title":"Unique metastatic patterns in neuroendocrine neoplasms of different primary origin","volume":"111","author":"Hermans","year":"2021","journal-title":"Neuroendocrinology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102168","article-title":"Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: a systematic review and meta-analysis","volume":"94","author":"Garcia-Torralba","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70115","article-title":"Bone metastases from neuroendocrine neoplasms: results of an Italian nationwide survey of natural history and management","volume":"38","author":"Fazio","year":"2026","journal-title":"J Neuroendocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/nu12041021","article-title":"Bone metabolism and vitamin D implication in gastroenteropancreatic neuroendocrine tumors","volume":"12","author":"Altieri","year":"2020","journal-title":"Nutrients"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01508-4","article-title":"TBS correlates with bone density and microstructure at trabecular and cortical bone evaluated by HR-pQCT","volume":"42","author":"Gama","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2176","article-title":"Trabecular bone score: a noninvasive analytical method based upon the DXA image","volume":"29","author":"Silva","year":"2014","journal-title":"J Bone Miner Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1530\/EC-14-0119","article-title":"Bone metastases and skeletal-related events from neuroendocrine tumors","volume":"4","author":"Van Loon","year":"2015","journal-title":"Endocr Connect"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000287255","article-title":"ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors","volume":"91","author":"Kos-Kud\u0142a","year":"2010","journal-title":"Neuroendocrinology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-04140-4","article-title":"Bone and muscle mass characteristics in patients with gastroenteropancreatic neuroendocrine neoplasms","volume":"88","author":"Aktypis","year":"2025","journal-title":"Endocrine"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226701","article-title":"Bone loss in patients with pancreatic neuroendocrine tumors","volume":"11","author":"Tong","year":"2022","journal-title":"J Clin Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/nu18020281","article-title":"Vitamin D deficiency and replacement challenges in type 1 gastric neuroendocrine tumors: a comparative study","volume":"18","author":"Benevento","year":"2026","journal-title":"Nutrients"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12270","article-title":"Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours","volume":"80","author":"Sen Gupta","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2012.02.637","article-title":"5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients","volume":"50","author":"van Dijk","year":"2012","journal-title":"Bone"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4174","article-title":"Circulating serotonin and bone density, structure, and turnover in carcinoid syndrome","volume":"98","author":"Walsh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/jne.70053","article-title":"Fragility fractures in well-differentiated gastroenteropancreatic neuroendocrine tumors: results from a multicentered retrospective study","volume":"37","author":"Brunetti","year":"2025","journal-title":"J Neuroendocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06817-4","article-title":"Update on the clinical use of trabecular bone score (TBS) in the management of osteoporosis: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), and the International Osteoporosis Foundation (IOF) under the auspices of WHO Collaborating Center for Epidemiology of Musculoskeletal Health and Aging","volume":"34","author":"Shevroja","year":"2023","journal-title":"Osteoporos Int"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2016.10.004","article-title":"Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: an enhanced screening approach incorporating trabecular bone score","volume":"7","author":"Mariotti","year":"2016","journal-title":"J Bone Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01063-0","article-title":"Trabecular bone score and quantitative ultrasound measurements in the assessment of bone health in breast cancer survivors assuming aromatase inhibitors","volume":"42","author":"Catalano","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01537-z","article-title":"Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapy","volume":"42","author":"Hara","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14090868","article-title":"Comparison of bone mineral density and trabecular bone score in patients with and without vertebral fractures and differentiated thyroid cancer with long-term serum thyrotrophin-suppressed therapy","volume":"14","author":"Hawkins Carranza","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgag069","article-title":"Effects of catecholamines on bone and mineral metabolism in patients with pheochromocytoma and paraganglioma","author":"Alkaissi","year":"2026","journal-title":"J Clin Endocrinol Metab"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2024.101501","article-title":"Impact of pheochromocytoma or paraganglioma on bone metabolism: a systemic review and meta-analysis","volume":"27","author":"Dutta","year":"2024","journal-title":"J Clin Densitom"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115607","article-title":"Role of deteriorated bone quality in the development of osteoporosis in pheochromocytoma and paraganglioma","volume":"142","author":"Yokomoto-Umakoshi","year":"2021","journal-title":"Bone"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/nu15173771","article-title":"Impact of vitamin D deficiency on tumor aggressiveness in neuroendocrine neoplasms","volume":"15","author":"Albertelli","year":"2023","journal-title":"Nutrients"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02869-w","article-title":"Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors","volume":"75","author":"Altieri","year":"2022","journal-title":"Endocrine"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2016.40","article-title":"Vitamin D and vitamin B12 deficiencies are common in patients with midgut carcinoid (SI-NET)","volume":"70","author":"Lind","year":"2016","journal-title":"Eur J Clin Nutr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000456619","article-title":"Impact of vitamin D on the clinical outcome of gastro-entero-pancreatic neuroendocrine neoplasms: report on a series from a single institute","volume":"105","author":"Massironi","year":"2017","journal-title":"Neuroendocrinology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2018.1470650","article-title":"Supplementation of vitamin D deficiency in patients with neuroendocrine tumors using over-the-counter vitamin D3 preparations","volume":"70","author":"Robbins","year":"2018","journal-title":"Nutr Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae343","article-title":"Nutritional status and quality of life of patients with advanced gastroenteropancreatic neuroendocrine neoplasms in Spain: the NUTRIGETNE (GETNE-S2109) study","volume":"30","author":"Olmo-Garc\u00eda","year":"2025","journal-title":"Oncologist"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/nu15122722","article-title":"Vitamin D intake, serum 25-hydroxyvitamin-D (25(OH)D) levels, and cancer risk: a comprehensive meta-meta-analysis including meta-analyses of randomized controlled trials and observational epidemiological studies","volume":"15","author":"Arayici","year":"2023","journal-title":"Nutrients"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16183211","article-title":"Vitamin D in cancer prevention and treatment: a review of epidemiological, preclinical, and cellular studies","volume":"16","author":"Dallavalasa","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/nu14071448","article-title":"Vitamin D and cancer: an historical overview of the epidemiology and mechanisms","volume":"14","author":"Mu\u00f1oz","year":"2022","journal-title":"Nutrients"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0038-9","article-title":"Exploring vitamin D metabolism and function in cancer","volume":"50","author":"Jeon","year":"2018","journal-title":"Exp Mol Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol31100456","article-title":"Searching for new biomarkers of neuroendocrine tumors: a comparative analysis of chromogranin A and inflammatory cytokines in patients with neuroendocrine tumors","volume":"31","author":"Budek","year":"2024","journal-title":"Curr Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.226","article-title":"Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel","volume":"33","author":"Yu","year":"2022","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.672499","article-title":"Are markers of systemic inflammatory response useful in the management of patients with neuroendocrine neoplasms","volume":"12","author":"Giannetta","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168569","article-title":"The role of miRNA in the pathophysiology of neuroendocrine tumors","volume":"22","author":"Geisler","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/biology13070505","article-title":"The involvement of microRNAs in bone remodeling signaling pathways and their role in the development of osteoporosis","volume":"13","author":"Jim\u00e9nez-Ortega","year":"2024","journal-title":"Biol (Basel)"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01740-7","article-title":"Direct effects of octreotide on osteoblast cell proliferation and function","volume":"45","author":"Vitali","year":"2022","journal-title":"J Endocrinol Invest"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2021.1881478","article-title":"Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia","volume":"20","author":"Panzuto","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/BF02409466","article-title":"Somatostatin can locally inhibit proliferation and differentiation of cartilage and bone precursor cells","volume":"33","author":"Weiss","year":"1981","journal-title":"Calcif Tissue Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1042\/bj2650039","article-title":"Identification and characterization of somatostatin receptors in neonatal rat long bones","volume":"265","author":"Bruns","year":"1990","journal-title":"Biochem J"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1186\/s12885-020-07506-9","article-title":"Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-021-00915-4","article-title":"Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT)","volume":"76","author":"Chan","year":"2022","journal-title":"Eur J Clin Nutr"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030782","article-title":"Prevalence of sarcopenia and impact on survival in patients with metastatic gastroenteropancreatic neuroendocrine tumours","volume":"15","author":"Clement","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/nu16223790","article-title":"High prevalence of sarcopenia in patients with newly diagnosed gastroenteropancreatic neuroendocrine tumours (GEP-NETs), but no association with the risk of surgical complications","volume":"16","author":"Clement","year":"2024","journal-title":"Nutrients"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/nu16142224","article-title":"Sarcopenia in patients with advanced gastrointestinal well-differentiated neuroendocrine tumors","volume":"16","author":"Romano","year":"2024","journal-title":"Nutrients"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/biom15121746","article-title":"Malnutrition and sarcopenia in patients with neuroendocrine tumors: A comprehensive review of evidence","volume":"15","author":"Poulia","year":"2025","journal-title":"Biomolecules"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133231","article-title":"Prognostic and predictive role of body composition in metastatic neuroendocrine tumor patients treated with everolimus: A real-world data analysis","volume":"14","author":"Ranallo","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/01635581.2022.2102660","article-title":"A combination of preoperative computed tomography-defined sarcopenia and systemic inflammation on survival in patients with poorly differentiated neuroendocrine neoplasms following radical resection","volume":"75","author":"Jia","year":"2023","journal-title":"Nutr Cancer"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1882735\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:38:28Z","timestamp":1782891508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1882735\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":57,"alternative-id":["10.3389\/fendo.2026.1882735"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1882735","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1882735"}}